Severs disease, also known as calcaneal apophysitis, is a common cause of heel pain in children. It occurs due to inflammation of the growth plate at the back of the heel bone. The common symptoms include pain in one or both heels, especially after periods of activity or exercise. Children aged 5 to 10 years are at increased risk of developing Severs disease as the growth plate cartilage is still growing at this stage. Growing participation in sports activities by children is also contributing to the rising incidence of heel pain.
The global severs disease treatment market is primarily driven by non-steroidal anti-inflammatory drugs (NSAIDs) which help reduce pain and inflammation. Other treatment options include rest, ice therapy, heel lifts or heel cups, stretching exercises, orthotics or custom shoe inserts.
The global severs disease treatment market is estimated to be valued at US$ 1.34 Bn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the severs disease treatment market are AstraZeneca , Horizon Therapeutics plc, Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd., Cipla Inc., LEO Pharma A/S, AbbVie Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Lonza, Lupin, Dr. Reddy’s Laboratories Ltd., IBSA Institut Biochimique SA. AstraZeneca is one of the leading players offering NSAIDs such as Naproxen and Ibuprofen for severs disease treatment.
The growing Severs Disease Treatment Market Size participation of children in sports and other recreational activities has increased the risk of heel pain. Rising focus on physical education in schools has also contributed to the higher incidence rates of Severs disease among kids. According to studies, 1 in 5 children may suffer from heel pain by the age of 10 years.
Geographically, North America dominates the global severs disease treatment market owing to established healthcare infrastructure and greater adoption of branded drugs. However, the Asia Pacific region is expected to exhibit lucrative growth opportunities during the forecast period attributed to rising healthcare spending, increasing incomes, and growing awareness about kids foot health issues.
Market Drivers
The increasing number of sports injuries among young athletes is a key driver for the severs disease treatment market. Rising obesity levels among children have also emerged as an important risk factor. Obese children are more prone to overuse of the growth plate of the heel bone leading to inflammation and pain. Growing awareness among parents about treatment options for children's heel pain problems through online health information and family doctors is boosting the severs disease therapeutics market growth.
The ongoing geopolitical tensions are expected to impact the growth of the severs disease treatment market over the forecast period. The instability caused due to conflicts and rising political uncertainties in different regions is anticipated to hamper the movement and supply chain of drugs and pharmaceutical products. This can lead to treatment delays and disrupt continuity of care, negatively influencing the overall market size. The market players need to devise robust mitigation strategies and contingency plans to minimize supply disruptions. They must consider alternative sourcing and manufacturing locations to de-risk their operations from geopolitical uncertainties. Collaborating with local partners in turbulent markets can help establish a resilient supply and distribution network. The companies should also explore partnerships with regional governments and trade bodies to voice concerns and ensure patient needs are prioritized despite ongoing geopolitical issues.
Currently, North America dominates the severs disease treatment market and accounts for the largest share in terms of value. This is attributed to the concentrated presence of major pharmaceutical companies and availability of advanced healthcare facilities in the region. Additionally, the high incidence of severs disease among children, rising healthcare expenditure, and growing public awareness regarding the condition also contribute to the significant market size of North America. However, over the forecast period, Asia Pacific is projected to exhibit the highest growth rate led by developing nations like India and China. This growth can be accredited to improving economic conditions, increasing medical tourism, rising disposable incomes, growing investments in healthcare infrastructure and expanding patient pool in Asia Pacific.
The Asia Pacific region holds huge potential for the severs disease treatment market led by rapidly developing economies and improving access to healthcare services. Countries such as India, China, Indonesia, Thailand and Vietnam continue to witness high economic progression which is positively impacting the overall healthcare industry in the region. Additionally, rising healthcare expenditures by both public and private players have significantly enhanced medical facilities and insurance penetration in Asia Pacific. Governments are also collaborating with pharmaceutical companies through favorable regulations and schemes to ensure affordability and accessibility of critical drugs. The abundance of generic alternatives further augments the preference for cost-effective treatments. These favorable factors are anticipated to drive robust market growth in Asia Pacific which offers immense opportunities for drug manufacturers.
Get more insights on Severs Disease Treatment Market
